BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$1.39 USD
+0.01 (0.72%)
Updated May 17, 2024 03:59 PM ET
After-Market: $1.49 +0.10 (7.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCTX 1.39 +0.01(0.72%)
Will BCTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BCTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BCTX
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Secures $5M in Funding
BriaCell falls on $5M stock offering
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Launches $5 Million Offering